SCYX on Nasdaq
SCYNEXIS INC
SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal.1
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with CASI Pharmaceuticals, Inc., Evofem Biosciences, Inc. or Prenetics Global Ltd, or pick any stock.
- TickerSCYX on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersJersey City, New Jersey1
- Business address1 Evertrust Plaza, 13Th Floor, Jersey City, Nj 07302-65482
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal infections. We are developing our proprietary antifungal platform “fungerps”, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis , Coccidioides , Histoplasma and Blastomyces genera and most common mucorales species.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
License and Service brought in 93% of the revenue SCYNEXIS INC broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| License and Service | $3.7M | $19.2M |
| Product | $0 | $1.4M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development61¢$22.3M
- Selling, general and admin39¢$14.4M
Out of $20.6M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $20.6M | $3.7M |
| Research and development | $22.3M | $26.4M |
| Selling, general and administrative | $14.4M | $14.5M |
| Total operating expenses | $36.7M | $40.9M |
| Loss from operations | -$16.1M | -$37.1M |
| Amortization of debt issuance costs and discount | $312.0K | $1.7M |
| Interest income | -$2.2M | -$4.3M |
| Interest expense | $173.0K | $828.0K |
| Other income | $0 | -$235.0K |
| Warrant liability fair value adjustment | -$5.8M | -$13.8M |
| Derivative liability fair value adjustment | $0 | -$196.0K |
| Total other income | -$7.5M | -$16.0M |
| Loss before taxes | -$8.6M | -$21.1M |
| Income tax expense | $0 | -$151.0K |
| Net loss | -$8.6M | -$21.3M |
| Net loss per share - basic | -$0.17 | -$0.44 |
| Net loss per share - diluted | -$0.17 | -$0.44 |
| Weighted average common shares outstanding - basic | 49.9M shares | 48.5M shares |
| Weighted average common shares outstanding - diluted | 49.9M shares | 48.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2014-04-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $21.3M | $16.1M | ||
| Short-term investments (Note 3) | $18.8M | $43.2M | ||
| Prepaid expenses and other current assets (Note 4) | $263.0K | $2.2M | ||
| License agreement receivable | $0 | $753.0K | ||
| License agreement contract asset | $0 | $9.5M | ||
| Restricted cash | $80.0K | $435.0K | ||
| Total current assets | $40.4M | $72.2M | ||
| Investments (Note 3) | $16.2M | $15.8M | ||
| Deferred offering costs | $533.0K | $417.0K | ||
| Restricted cash | $109.0K | $109.0K | ||
| Operating lease right-of-use asset (Note 6) | $1.8M | $2.1M | ||
| Total assets | $59.0M | $90.6M | ||
| Accounts payable | $2.2M | $4.6M | ||
| Accrued expenses (Note 5) | $2.8M | $3.8M | ||
| Deferred revenue, current portion | $235.0K | $1.6M | ||
| Operating lease liability, current portion (Note 6) | $483.0K | $407.0K | ||
| Convertible debt and derivative liability (Note 6) | $0 | $13.7M | ||
| Total current liabilities | $5.7M | $24.1M | ||
| Deferred revenue | $0 | $1.3M | ||
| Warrant liability | $2.2M | $8.0M | ||
| Operating lease liability (Note 6) | $1.7M | $2.2M | ||
| Total liabilities | $9.7M | $35.6M | ||
| Preferred stock, $0.001 par value, authorized 5,000,000 shares as of December 31, 2025 and 2024; 0 shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.001 par value, 150,000,000 shares authorized as of December 31, 2025 and 2024; 43,541,510 and 37,973,991 shares issued and outstanding as of December 31, 2025, and 2024, respectively | $46.0K | $41.0K | ||
| Additional paid-in capital | $434.5M | $431.6M | ||
| Accumulated deficit | -$385.1M | -$376.5M | ||
| Total stockholders equity | $49.4M | $55.1M | $73.0M | |
| Total liabilities and stockholders equity | $59.0M | $90.6M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 5.0M shares | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 150.0M shares | 150.0M shares | ||
| Common stock, shares issued (in shares) | 43.5M shares | 38.0M shares | ||
| Common stock, shares outstanding (in shares) | 43.5M shares | 38.0M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2014-04-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $21.3M | $16.1M | ||
| Short-term investments (Note 3) | $18.8M | $43.2M | ||
| Prepaid expenses and other current assets (Note 4) | $263.0K | $2.2M | ||
| License agreement receivable | $0 | $753.0K | ||
| License agreement contract asset | $0 | $9.5M | ||
| Restricted cash | $80.0K | $435.0K | ||
| Total current assets | $40.4M | $72.2M | ||
| Investments (Note 3) | $16.2M | $15.8M | ||
| Deferred offering costs | $533.0K | $417.0K | ||
| Restricted cash | $109.0K | $109.0K | ||
| Operating lease right-of-use asset (Note 6) | $1.8M | $2.1M | ||
| Total assets | $59.0M | $90.6M | ||
| Accounts payable | $2.2M | $4.6M | ||
| Accrued expenses (Note 5) | $2.8M | $3.8M | ||
| Deferred revenue, current portion | $235.0K | $1.6M | ||
| Operating lease liability, current portion (Note 6) | $483.0K | $407.0K | ||
| Convertible debt and derivative liability (Note 6) | $0 | $13.7M | ||
| Total current liabilities | $5.7M | $24.1M | ||
| Deferred revenue | $0 | $1.3M | ||
| Warrant liability | $2.2M | $8.0M | ||
| Operating lease liability (Note 6) | $1.7M | $2.2M | ||
| Total liabilities | $9.7M | $35.6M | ||
| Preferred stock, $0.001 par value, authorized 5,000,000 shares as of December 31, 2025 and 2024; 0 shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.001 par value, 150,000,000 shares authorized as of December 31, 2025 and 2024; 43,541,510 and 37,973,991 shares issued and outstanding as of December 31, 2025, and 2024, respectively | $46.0K | $41.0K | ||
| Additional paid-in capital | $434.5M | $431.6M | ||
| Accumulated deficit | -$385.1M | -$376.5M | ||
| Total stockholders equity | $49.4M | $55.1M | $73.0M | |
| Total liabilities and stockholders equity | $59.0M | $90.6M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 5.0M shares | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 150.0M shares | 150.0M shares | ||
| Common stock, shares issued (in shares) | 43.5M shares | 38.0M shares | ||
| Common stock, shares outstanding (in shares) | 43.5M shares | 38.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net (loss) income | -$8.6M | -$21.3M |
| Stock-based compensation expense | $2.9M | $3.3M |
| Accretion of investment discount | -$474.0K | -$1.3M |
| Amortization of debt issuance costs and discount | $312.0K | $1.7M |
| Change in fair value of warrant liabilities | -$5.8M | -$13.8M |
| Change in fair value of derivative liability | $0 | -$196.0K |
| Noncash operating lease expense for right-of-use asset | $326.0K | $272.0K |
| Prepaid expenses and other current assets, deferred costs, and other | $2.2M | $3.4M |
| License agreement contract asset | $9.5M | $9.9M |
| License agreement receivable | $753.0K | $1.7M |
| Accounts payable | -$2.2M | -$2.6M |
| Accrued expenses | -$1.0M | -$3.7M |
| Deferred revenue | -$2.7M | -$979.0K |
| Other liabilities and other | -$407.0K | -$339.0K |
| Net cash used in operating activities | -$5.3M | -$24.0M |
| Purchase of investments | -$18.9M | -$36.4M |
| Maturity of investments | $43.2M | $42.6M |
| Net cash provided by investing activities | $24.3M | $6.2M |
| Proceeds from common stock issued | $5.0K | $0 |
| Payment of convertible debt | -$14.0M | $0 |
| Payments of deferred offering costs | -$226.0K | -$195.0K |
| Proceeds from employee stock purchase plan issuances | $51.0K | $56.0K |
| Net cash used in financing activities | -$14.2M | -$139.0K |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $4.9M | -$18.0M |
| Cash paid for interest | $420.0K | $840.0K |
| Cash received for interest | $2.1M | $3.3M |
| Deferred offering and issuance costs included in accounts payable | $0 | $110.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led SCYNEXIS INC, and when. Pick a name to see everywhere that person has worked.
President
Chief financial officer
201520202025
- Chief executive officerGonzalez David Angulo Jan 3, 2023 to now13
- Chief executive officerMarco Taglietti Apr 3, 2015 to Apr 28, 202214
- Chief executive officerYves J. Ribeill May 2, 2014 to Jun 20, 201415
- PresidentYves J. Ribeill May 2, 2014 to Apr 3, 201515
- Chief financial officerSanjay Subramanian Sep 11, 2026 to now16
- Chief financial officerIvor Macleod Oct 26, 2022 to Sep 11, 202617
- Chief financial officerLawrence R. Hoffman Dec 2, 2021 to Dec 2, 202118
- Chief financial officerJonathan Sears Woodall Jul 31, 2015 to Jul 31, 201519
- Chief financial officerEric Francois Nov 3, 2015 to Feb 2, 202120
- Chief financial officerCharles F. Osborne Jr. May 2, 2014 to Apr 3, 201521
Board members and other officers (23)
- Chief Medical OfficerGonzalez David Angulo Jun 5, 2015 to Feb 8, 202222
- Chief Medical OfficerCarole Sable May 2, 2014 to Jun 20, 201423
- Vice PresidentMichael C. Garrett May 2, 2014 to May 2, 201424
- VP of Animal HealthVivian W. Doelling May 2, 2014 to May 2, 201425
- Board memberGonzalez David Angulo Jan 30, 2024 to now26
- Board memberArmando Anido Jan 23, 2019 to now27
- Board memberBrian Philippe Tinmouth Dec 17, 2019 to now28
- Board memberMarion McCourt Jan 27, 2017 to Jul 3, 201829
- Board memberSteven C. Gilman Feb 27, 2015 to now30
- Board memberClarence Patrick Machado Sep 28, 2015 to Jan 4, 201931
- Board memberDavid C. Hastings Sep 28, 2015 to now32
- Board memberAnn Hanham May 2, 2014 to now33
- Board memberEdward Penhoet May 2, 2014 to Jun 5, 201534
- Board memberJean-Yves Nothias May 2, 2014 to Apr 3, 201535
- Board memberLaurent Arthaud May 2, 2014 to Jun 13, 201436
- Board memberMounia Chaoui May 2, 2014 to Jun 13, 201437
- Board memberPamela J. Kirby May 2, 2014 to Apr 3, 201538
- Board memberPatrick Langlois May 2, 2014 to Jan 5, 201739
- Board memberYves J. Ribeill May 2, 2014 to Jul 24, 201515
- Board memberGuy Macdonald Dec 3, 2014 to now40
- Board memberMarco Taglietti Dec 3, 2014 to Apr 28, 202241
- General counselScott Sukenick Nov 17, 2017 to now42
- General counselEileen Pruette May 2, 2014 to Jun 20, 201443
Timeline
Filings
226 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 37 major events, 66 insider forms, 40 large holders, 62 other. The latest 20:
- Sep 28, 20268-K EDGAR
- Sep 22, 20264 EDGAR
- Sep 22, 20263 EDGAR
- Sep 22, 20268-K EDGAR
- Sep 11, 20264 EDGAR
- Sep 11, 20263 EDGAR
- Sep 10, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 2026SCHEDULE 13G EDGAR
- Aug 10, 2026S-8 EDGAR
- Aug 10, 202610-Q EDGAR
- Jul 20, 2026SCHEDULE 13G/A EDGAR
- Jul 8, 2026SCHEDULE 13G/A EDGAR
- Jun 30, 20264 EDGAR
- Jun 30, 20264 EDGAR
- Jun 30, 20264 EDGAR
- Jun 30, 20264 EDGAR
- Jun 30, 20264 EDGAR
- Jun 26, 20268-K EDGAR
The 226 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Angulo Gonzalez DavidChief Executive Officer | Buy | 108,695 | Form 4 | ||
| Sep 12, 2024 | Angulo Gonzalez DavidChief Executive Officer | Buy | 20,000 | $1.37 | $27.4K | Form 4 |
| Apr 26, 2022 | Taglietti MarcoChief Executive Officer | Buy | 75,000 | $3.00 | $225.0K | Form 4 |
| Apr 26, 2022 | Sukenick ScottChief Legal Officer | Buy | 3,500 | $3.00 | $10.5K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- CVI Investments, Inc.SCHEDULE 13G/A, 3 filings Apr 28, 2026 to Aug 14, 202644
- GREAT POINT PARTNERS LLCSCHEDULE 13G/A, 2 filings Apr 7, 2026 to Aug 14, 202645
- Adage Capital Management, L.P.SCHEDULE 13G, 1 filing Aug 12, 202646
- Squadron Capital Management LLCSCHEDULE 13G, 1 filing Apr 8, 202647
- Avidity Partners Management LPSCHEDULE 13G/A, 7 filings Feb 14, 2022 to Feb 17, 202648
- KINGDON CAPITAL MANAGEMENT, L.L.C.SCHEDULE 13G/A, 4 filings Apr 13, 2023 to Feb 17, 202649
- CAXTON CORPSC 13G/A, 2 filings Feb 14, 2022 to Feb 13, 202450
- Stonepine Capital Management, LLCSC 13G/A, 3 filings Feb 14, 2022 to Feb 13, 202451
- Orin HirschmanSC 13G/A, 4 filings Nov 12, 2021 to Apr 3, 202352
- ARMISTICE CAPITAL, LLCSC 13G/A, 1 filing Feb 14, 202353
- PERCEPTIVE ADVISORS LLCSC 13G/A, 1 filing Feb 14, 202254
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 39. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARSCYNEXIS INC filings on SEC EDGAR
- 2SEC EDGARSCYNEXIS INC filings on SEC EDGAR
- 3
- 4SEC EDGARSCYNEXIS INC 10-K for fiscal 2025
- 5SEC EDGARSCYNEXIS INC 10-K for fiscal 2019
- 6SEC EDGARSCYNEXIS INC 10-K for fiscal 2020
- 7SEC EDGARSCYNEXIS INC 10-K for fiscal 2021
- 8SEC EDGARSCYNEXIS INC 10-K for fiscal 2022
- 9SEC EDGARSCYNEXIS INC 10-K for fiscal 2023
- 10SEC EDGARSCYNEXIS INC 10-Q for fiscal 2026
- 11SEC EDGARSCYNEXIS INC 10-Q for fiscal 2026
- 12SEC EDGARSCYNEXIS INC 10-K for fiscal 2019
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23SEC EDGARCarole Sable, Chief Medical Officer
- 24SEC EDGARMichael C. Garrett, Vice President
- 25
- 26SEC EDGARGonzalez David Angulo, Board member
- 27SEC EDGARArmando Anido, Board member
- 28
- 29SEC EDGARMarion McCourt, Board member
- 30SEC EDGARSteven C. Gilman, Board member
- 31
- 32SEC EDGARDavid C. Hastings, Board member
- 33SEC EDGARAnn Hanham, Board member
- 34SEC EDGAREdward Penhoet, Board member
- 35SEC EDGARJean-Yves Nothias, Board member
- 36SEC EDGARLaurent Arthaud, Board member
- 37SEC EDGARMounia Chaoui, Board member
- 38SEC EDGARPamela J. Kirby, Board member
- 39SEC EDGARPatrick Langlois, Board member
- 40SEC EDGARGuy Macdonald, Board member
- 41SEC EDGARMarco Taglietti, Board member
- 42SEC EDGARScott Sukenick, General counsel
- 43SEC EDGAREileen Pruette, General counsel
- 44
- 45
- 46
- 47
- 48
- 49
- 50SEC EDGARCAXTON CORP SC 13G/A on SCYNEXIS INC
- 51
- 52
- 53
- 54